Safety of Tofacitinib vs Biologics in PsA: One Risk Differs

Published Date: 10 Apr 2026

Tofacitinib shows safety comparable with biologics for PsA regarding serious infections, myocardial infarction or stroke, and malignancy but is tied to a higher risk for VTE than TNF inhibitors.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does pollution cause cancer?

2.

AI is equally capable of reading breast cancer scans as human radiologists.

3.

EVP Beats Cisplatin for Resectable MIBC

4.

New research points out a promising strategy for treating metastatic medulloblastoma

5.

Academics + Pharma = Big Bucks; New CAR-T Warnings; Patients Seek Cancer Tests.


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot